297 related articles for article (PubMed ID: 7970192)
21. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys.
Villalba RM; Lee H; Smith Y
Exp Neurol; 2009 Feb; 215(2):220-7. PubMed ID: 18977221
[TBL] [Abstract][Full Text] [Related]
22. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
23. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
Oeckl P; Ferger B
Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
25. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Rose S; Nomoto M; Kelly E; Kilpatrick G; Jenner P; Marsden CD
Neurosci Lett; 1989 Jul; 101(3):305-10. PubMed ID: 2505199
[TBL] [Abstract][Full Text] [Related]
26. Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys.
Elsworth JD; Brittan MS; Taylor JR; Sladek JR; al-Tikriti MS; Zea-Ponce Y; Innis RB; Redmond DE; Roth RH
Cell Transplant; 1996; 5(2):315-25. PubMed ID: 8689042
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
28. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
Schneider JS; Yuwiler A; Markham CH
Brain Res; 1987 May; 411(1):144-50. PubMed ID: 2886180
[TBL] [Abstract][Full Text] [Related]
29. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
30. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
31. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
32. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
[TBL] [Abstract][Full Text] [Related]
33. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
34. Cerebral metabolism of parkinsonian primates 21 days after MPTP.
Schwartzman RJ; Alexander GM; Ferraro TN; Grothusen JR; Stahl SM
Exp Neurol; 1988 Dec; 102(3):307-13. PubMed ID: 3264247
[TBL] [Abstract][Full Text] [Related]
35. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells.
German DC; Manaye KF; Sonsalla PK; Brooks BA
Ann N Y Acad Sci; 1992 May; 648():42-62. PubMed ID: 1353337
[TBL] [Abstract][Full Text] [Related]
36. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
37. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Rai SN; Yadav SK; Singh D; Singh SP
J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
[TBL] [Abstract][Full Text] [Related]
38. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
39. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
[TBL] [Abstract][Full Text] [Related]
40. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
